

DELAYED GASTRIC EMPTYING


Anaesthetic risks



Dr. Surendra Ugale

Ayushka & Akshan Ugale, Praveen Reddy, Trilok

Kirloskar Hospital, Udai Omni & KIMS-Arete, Hyderabad, INDIA



Dr. Percy Brante

Clínica Las Condes

Santiago, Chile

Disclosure

[X] -- We have no conflicts of interest to report



OMM/AOM: THE BIGGEST SURPRISE AND NIGHTMARE FOR THE SURGEON NOWADAYS



SERRIE

IFSO
XXIX IFSO
World Congress

1-4 September 2026
Toronto, Canada

TORONTO2026 The Future of Obesity Management:
From Weight Loss to Health Gain



- Current combined-therapy patients may have obesity, diabetes, altered foregut anatomy and a GLP-1 /GIP drug.
- Standard fasting history → Unreliable


Kindel TL et al. Multi-society GLP-1 perioperative guidance. Surg Obes Relat Dis. 2024;20:1183–1191.




A fasted patient may still have a full stomach



How Ozempic Works



How Mounjaro Works



AOM / OMM → Increased Residual Gastric Contents {RGC} → Reduces airway protection

1. Before / After Metabolic Surgery / Any Surgery
2. Endoscopy procedures
3. Revision Surgery

- MHRA. GLP-1/GIP agonists: pulmonary aspiration warning. Drug Safety Update. 28 Jan 2025.
- Kindel TL et al. Multi-society GLP-1 perioperative guidance. Surg Obes Relat Dis. 2024;20:1183–1191.



Combining AOM / OMM → a new “full stomach”

PATIENT

Obesity
Diabetes
OSA
GERD

MEDICINE

Semaglutide
Tirzepatide
Opioids

ANATOMY

Sleeve / bypass
Stricture
Hiatal hernia

PROCEDURE

GA or deep Sedation
Pneumoperitoneum
Airway loss

***Multiplication of Risk : drug effect + disease + anatomy + anaesthetic technique.**

- MHRA Drug Safety Update. 28 Jan 2025
- Kindel TL et al. 2024 multi-society guidance



GLP-1/GIP signalling slows the stomach—especially early phase

FUNDUS

Reduced accommodation may promote fullness

ANTRUM

Lower propulsive motility

PYLORUS

Higher resistance / altered coordination

BRAIN-VAGUS

Satiety, nausea and autonomic modulation

Greatest concern: dose escalation, higher dose, weekly agents and active GI symptoms.

- Kindel TL et al. Surg Obes Relat Dis. 2024
- Nauck MA et al. Diabetes Obes Metab. 2011;13 Suppl 1:5–13



Standard fasting does not prevent residual Gastric contents

56%

GLP-1 users

19%

matched non-users

124 fasted elective patients

**Increased residual gastric content
on pre-procedure ultrasound**

Fasting history is necessary— BUT – No Guarantee !!!

- Sen S et al. GLP-1 use and residual gastric content before anaesthesia. JAMA Surg. 2024;159:660–667.



Symptoms / Look-out Signs

1. Nausea, vomiting, bloating or early satiety
2. Abdominal pain or constipation
3. Delayed emptying is strongest effect with first few doses
4. With Increase of dose:
Reflux, regurgitation or nocturnal cough

- MHRA. GLP-1/GIP agonists: pulmonary aspiration warning. Drug Safety Update. 28 Jan 2025.
- Kindel TL et al. Multi-society GLP-1 perioperative guidance. Surg Obes Relat Dis. 2024;20:1183–1191.



Residual Gastric content Increases..... BUT aspiration is Uncommon

56% vs 19%

Increased Gastric Content

RR 1.00

Elective Surgery Aspiration
95% CI 0.76–1.30

Large Cohort → 366,476

No increased postoperative
aspiration pneumonia

Conclusion : Identify the occasional high-risk individual for greater Precautions

- Sen S et al. GLP-1 use and residual gastric content before anaesthesia. JAMA Surg. 2024;159:660–667.
- Ho CN et al. Aspiration and pulmonary complications: systematic review/meta-analysis. J Endocr Soc. 2025;9:bvaf088.
- Chen YH et al. Postoperative aspiration pneumonia in 366,476 adults. JAMA Netw Open. 2025;8:e250081.



Stopping the drug → does not ensure gastric-emptying

Daily / weekly

Half-life varies widely

One missed dose

May not reverse physiology

- *2023 ASA advice recommended holding daily drugs for 1 day and weekly drugs for seven days.
- *2024 multi-society guidance shifted to individualized risk assessment
- * 2026 prospective study found increased RGC in 42% even after weekly GLP-1 stoppage ≥ 7 days vs 24% controls, statistically insignificant

7-day interruption

Residual content can persist

Long interruption

Hyperglycaemia, hunger, weight rebound

- ASA consensus guidance. 2023
- Kindel TL et al. 2024
- Boudreau C et al. BMC Anesthesiol. 2026; doi:10.1186/s12871-026-03999-2



Current guidance: continue most patients—Isolate the high-risk ones

LOW RISK

Stable maintenance dose
No GI symptoms
No added gastroparesis risks

Continue therapy
Standard fasting

HIGHER RISK

Escalation or high dose
Symptoms
Diabetes/autonomic disease

24-h liquid-only diet

UNACCEPTABLE / UNCERTAIN

Solid contents
Severe symptoms
No safe airway plan

Postpone elective case
or treat as full stomach

*2024 ASA-led multi-society (Incl ASMBS) guidance → Continue GLP-1 agents in patients without elevated risk.
For higher risk, use a liquid-only diet for 24-48 hours, check with gastric ultrasound.



Precautions to reduce aspiration risk – Individualised Technique

BEFORE

Antacids
Suction ready
Skilled assistance

INDUCTION

Head-up position
Preoxygenate
Rapid-sequence
induction with
tracheal intubation

AIRWAY

Cuffed tracheal tube
Avoid deep sedation
without rescue
capacity

EXTUBATION

Fully awake
Protective reflexes
restored
Plan postop monitoring

Gastric ultrasound can be useful

Kindel TL et al. Multi-society GLP-1 perioperative guidance. Surg Obes Relat Dis. 2024;20:1183–1191.
ASA Practice Guidelines for Preoperative Fasting. Anesthesiology. 2023
Perlas A et al. Validation of gastric sonography assessment. Anesth Analg. 2013;116:357–363.



Considerations in Endoscopy and emergency surgery

UPPER GI ENDOSCOPY

Retained food impairs visibility
Deep sedation may leave airway
unprotected

EMERGENCY SURGERY

Do not delay necessary surgery
Assume full stomach
Use protected airway strategy

BARIATRIC REVISION

Obstruction or stenosis make
Decompression difficult
Surgeon–anaesthetist plan
before induction

Kindel TL et al. Multi-society GLP-1 perioperative guidance. Surg Obes Relat Dis. 2024;20:1183–1191.
MHRA. GLP-1/GIP agonists: pulmonary aspiration warning. Drug Safety Update. 28 Jan 2025.




Conclusion & Take Home Messages

- 1 Specific medical history → GLP-1/GIP and other motility-slowing drugs.
- 2 Screen for diabetes gastroparesis, reflux, opioids and obstructive symptoms
Fasting -- cannot ensure an empty stomach.
- 3 Residual gastric content is increased; aspiration risk is not.
- 4 When uncertain : USG, protect the airway, and continue.....or else postpone
- 5 Decision is not “stop or continue”—it is “how do we make this patient safe?”



T
H
A
N
K

Y
O
U



T
H
A
N
K

Y
O
U